Breast Cancer Clinical Trial
Official title:
Follow-Up Observational Study In CHAT Trial Participants With Advanced And/Or Metastatic Breast Cancers That Overexpress HER2, Who Were Randomised To Receive Trastuzumab And Docetaxel With Or Without Capecitabine
The aim of the CHAT study ("An open-label, randomized Phase II study of Herceptin
(trastuzumab), Taxotere® (docetaxel) and Xeloda (capecitabine) in combination, versus
Herceptin (trastuzumab) plus Taxotere® (docetaxel), in patients with advanced and/or
metastatic breast cancers that overexpress HER2") was to test the combination of Trastuzumab
and Docetaxel with or without capecitabine as first-line therapy for HER2 positive locally
advanced or metastatic breast cancer.
Overall Response Rate was the primary endpoint of the CHAT study. This study failed to meet
its primary objective of showing a difference between the treatment groups, with equivalent
high response rates for the Trastuzumab plus Docetaxel and Trastuzumab, Docetaxel plus
capecitabine arms.
Secondary endpoints in the CHAT study were Progression-Free-Survival, Time-to-Progression,
Overall Survival, duration of response and safety profile. Whilst analysis of the existing
data is consistent with improvement with the triplet therapy, interpretation is compromised
by the relatively short median follow-up of 24 months. In hindsight the statistical design
was flawed by selection of a sub optimal primary endpoint and consequently data was
collected and analysed early in relation to time-dependent endpoints. Beyond CHAT will
permit capture of mature data for time-related endpoints. Time-to-Progression and Overall
Survival are the co-primary endpoints for the Beyond CHAT protocol. The impact of treatment
following the first progression, on survival, will be explored.
Time-to-Progression will be defined from the time interval between the date of randomisation
and the occurrence of progressive disease under therapy according to RECIST criteria.
Overall Survival will be defined as the time from date of randomisation to date of death
The objective of this study is to gain mature data on the long-term efficacy of the
combination of Trastuzumab and Docetaxel with or without capecitabine as first-line therapy
for HER2 positive locally advanced or metastatic breast cancer.
The study also aims to gain information on the additional treatments and sequencing used in
patients that have progressed following the combination of Trastuzumab and Docetaxel with or
without capecitabine as first-line therapy for HER2 positive locally advanced or metastatic
breast cancer.
Overall Survival data on patients who have progressed following the combination of
Trastuzumab and Docetaxel with or without capecitabine as first-line therapy for HER2
positive locally advanced or metastatic breast cancer will also be analysed and reported.
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |